Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.